Ann: Return of Capital - MYX (updated), page-21

Rose coloured Glasses is an understatement for
your assessment of Nextellis. So far Mayne have
spent approximately $200m on this first in 50 years
groundbreaking pill. Deal with the facts. The former
MD of Mithra bought the rights to this product from
another company he and his crony mates owned. They
paid hugely inflated price’s therefore giving Mithra a
massive boost in SP. The guy is a crook who our
previous CEO got involved with firstly with Haloette.
so long ago. Mayne hung its coat tails on for ages.
They we’re going to be first to market 4 years ago
now recently FDA approved not even price sensitive.
Then Nextellis In reality it’s like a new ice cream flavour.
Different , but the market still likes Vanilla, Chocolate and
Strawberry. The expected revenue this year is $20m
Seriously you say it will take time would anyone in
their right mind accept a deal $200m costs after 2+
years selling for revenue $20m if you knew upfront.
I think not. The SP of Mithra tells the story. Nearly
40 € now 3.5€. The SP of Mayne speaks volumes
as well. You would be wise to take note of long term
holders who exactly like yourself have been misled
particularly by the likes of Richards and Fornieri. Both
former MDs unfortunately only one facing criminal
charges . Associating with these types can only lead
ine way.